Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors

DISEASE CHARACTERISTICS: * Histologically confirmed newly diagnosed or recurrent supratentorial primary or metastatic malignant brain tumor * Measurable disease by MRI or CT scan * Candidate for surgical resection * Extension of tumor no more than 1.0 cm beyond the margin of the surgical cavity * Demonstrated reactivity of tumor cells with tenascin by immunohistology with either a polyclonal rabbit antibody or the monoclonal mouse antibody * No infratentorial tumors, diffusely infiltrating tumors, tumors with subependymal spread, or multifocal tumors PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 50-100% Life expectancy: * Not specified Hematopoietic: * Absolute neutrophil count greater than 1000/mm\^3 * Platelet count greater than 100,000/mm\^3 Hepatic: * Bilirubin less than 1.5 mg/dL * Alkaline phosphatase less than 1.5 times normal * SGOT less than 1.5 times normal Renal: * Creatinine less than 1.2 mg/dL Other: * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * At least 6 weeks since prior chemotherapy, unless unequivocal evidence of progression Endocrine therapy: * Concurrent corticosteroids allowed, but must be on stable dose for at least 1 week Radiotherapy: * At least 3 months since prior radiotherapy to site of measurable disease in the CNS Surgery: * See Disease Characteristics